Systematic evaluation of donor-KIR/recipient-HLA interactions in HLA-matched hematopoietic cell transplantation for AML

Author:

Fein Joshua A.1ORCID,Shouval Roni2ORCID,Krieger Elizabeth3ORCID,Spellman Stephen R.4,Wang Tao45ORCID,Baldauf Henning6,Fleischhauer Katharina7ORCID,Kröger Nicolaus8ORCID,Horowitz Mary5,Maiers Martin4ORCID,Miller Jeffrey S9,Mohty Mohamad10,Nagler Arnon11ORCID,Weisdorf Daniel9ORCID,Malmberg Karl-Johan12ORCID,Toor Amir A.13ORCID,Schetelig Johannes614ORCID,Romee Rizwan15ORCID,Koreth John15

Affiliation:

1. 1Depatment of Hematology and Medical Oncology, Weill Cornell Medicine, New York Presbyterian Hospital, New York, NY

2. 2Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

3. 3Children’s Hospital of Richmond, Virginia Commonwealth University, Richmond, VA

4. 4Center for International Blood and Marrow Transplant Research, National Marrow Donor Program/Be The Match, Minneapolis, MN

5. 5Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI

6. 6Clinical Trials Unit, DKMS Bone Marrow Registry, Tübingen, Germany

7. 7Institute for Experimental Cellular Therapy, University Hospital Essen, Essen, Germany

8. 8Department of Stem Cell Transplantation, University Hospital Hamburg-Eppendorf, Hamburg, Germany

9. 9Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, MN

10. 10Department of Hematology, Saint Antoine Hospital, Sorbonne University, Paris, France

11. 11Division of Hematoloy, Chaim Sheba Medical Center, Tel HaShomer, Israel

12. 12Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway

13. 13Topper Cancer Institute, Lehigh Valley Health Network, Allentown, PA

14. 14Medizinische Klinik I, University Hospital TU Dresden, Dresden, Germany

15. 15Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA

Abstract

Abstract In acute myeloid leukemia (AML), donor natural killer cell killer immunoglobulin–like receptors (KIR) and recipient HLA interactions may contribute to the graft-versus-leukemia effect of allogeneic hematopoietic cell transplantation (HCT). Analyses of individual KIR/HLA interactions, however, have yielded conflicting findings, and their importance in the HLA-matched unrelated donor (MUD) setting remains controversial. We systematically studied outcomes of individual donor-KIR/recipient-HLA interactions for HCT outcomes and empirically evaluated prevalent KIR genotypes for clinical benefit. Adult patients with AML (n = 2025) who received HCT with MUD grafts in complete remission reported to the Center for International Blood and Marrow Transplantation were evaluated. Only the donor-2DL2+/recipient-HLA-C1+ pair was associated with reduced relapse (hazard ratio [HR], 0.79; 95% confidence interval [CI], 0.67-0.93; P = .006) compared with donor-2DL2–/recipient-HLA-C1+ pair. However, no association was found when comparing HLA-C groups among KIR-2DL2+–graft recipients. We identified 9 prevalent donor KIR genotypes in our cohort and screened them for association with relapse risk. Genotype 5 (G5) in all recipients and G3 in Bw4+ recipients were associated with decreased relapse risk (HR, 0.52; 95% CI, 0.35-0.78; P = .002; and HR, 0.32; 95% CI, 0.14-0.72; P = .006; respectively) and G2 (HR 1.63, 95% CI, 1.15-2.29; P = .005) with increased relapse risk in C1-homozygous recipients, compared with other patients with the same ligand. However, we could not validate these findings in an external data set of 796 AML transplants from the German transplantation registry. Neither a systematic evaluation of known HLA-KIR interactions nor an empiric assessment of prevalent KIR genotypes demonstrated clinically actionable associations; therefore, these data do not support these KIR-driven strategies for MUD selection in AML.

Publisher

American Society of Hematology

Subject

Hematology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3